<DOC>
	<DOCNO>NCT01308541</DOCNO>
	<brief_summary>The purpose study explore pharmacokinetics ( PK ) pharmacodynamics ( PD ) LUSEDRA® administer continuous infusion bolus compare continuous infusion propofol injectable emulsion .</brief_summary>
	<brief_title>A Study Characterize Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) LUSEDRA® Administered Continuous Infusion Bolus Compared With Continuous Infusion Propofol Injectable Emulsion</brief_title>
	<detailed_description>The study design explore pharmacokinetics ( PK ) pharmacokinetic/ pharmacodynamic ( PK/PD ) relationship PK-Bispectral Index ( BIS ) PK-Modified Observer 's Assessment Alertness/Sedation ( MOAA/S ) score follow administration LUSEDRA , administer bolus continuous infusion , propofol injectable emulsion administer continuous infusion , use compartmental modeling . The clinical practice sedation span entire continuum sedation , portion currently address currently approve dose intend provide moderate level sedation . Another goal current study support potential follow-up indication fospropofol disodium , prolonged sedation Intensive Care Unit ( ICU ) induction maintenance general anesthesia , require high dos . If successful , data study would allow direct comparison propofol dos , deliver fospropofol disodium propofol injectable emulsion , provide sedation effect directly compare concentration-effect relation propofol liberate fospropofol disodium deliver propofol . The dos infusion time fospropofol disodium propofol study select base simulation result use establish PK/PD model develop historical data . Data collect current study use refine exist PK/PD model . To enhance robustness model , study design include change dose duration sedation three treatment group .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Fospropofol</mesh_term>
	<criteria>Inclusion : Nonsmoking male female subject , age &gt; /= 18 &lt; /= 45 year old Screening . Exclusion : Body mass index ( BMI ) &gt; /= 30 Subjects smoke use nicotine nicotinecontaining product within 18 month Screening throughout study Subjects know history clinically significant drug food allergy , include allergy ingredient either medication ( fospropofol disodium propofol injectable emulsion ) presently experience significant seasonal allergy Subjects allergic egg , egg product , soybean , soy product Subjects past current medical history respiratory illness include asthma sleep apnea Subjects disorder fat metabolism , predispose fat embolism , condition lipid emulsion must use carefully Subjects currently take medication include overthecounter ( OTC ) medication ( within 14 day prior Baseline Period 1 ) exception hormonal contraceptive hormone replacement therapy , long subject stable dose product least 12 week prior dose . Use 1.0 % lidocaine &lt; 1.0 mL placement arterial line allow .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>